Expression of Asialoglycoprotein Receptor 1 in Human Hepatocellular Carcinoma

Journal of Histochemistry and Cytochemistry

Volumn 61, Issue 12, 2013, Pages 901-909

  Shi, Bin ^a   Abrams, Marc ^a   Sepp Lorenzino, Laura ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ASGPR; galactosamine; galactose; human hepatocellular carcinoma (HCC); immunohistochemistry; targeting delivery

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; ASIALOGLYCOPROTEIN RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASOLATERAL MEMBRANE; BILE DUCT CARCINOMA; CHRONIC ACTIVE HEPATITIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ASGPR; GALACTOSAMINE; GALACTOSE; HUMAN HEPATOCELLULAR CARCINOMA (HCC); IMMUNOHISTOCHEMISTRY; TARGETING DELIVERY;

ASIALOGLYCOPROTEIN RECEPTOR; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS;

EID: 84888368664     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155413503662     Document Type: Article

References (36)

1. Ashwell G,Morell AG.The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins.Adv Enzymol Relat Areas Mol Biol. 1974;41:99-128.
2. Au SL,Wong CC,Lee JM,Fan DN,Tsang FH,Ng IO,Wong CM.Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.Hepatology. 2012;56:622-631.
3. Boers JE,Meeuwissen H,Methorst N.HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).Histopathology. 2011;58:383-394.
4. Burchard J,Zhang C,Liu AM,Poon RT,Lee NP,Wong KF,Sham PC,Lam BY,Ferguson MD,Tokiwa G,Smith R,Leeson B,Beard R,Lamb JR,Lim L,Mao M,Dai H,Luk JM.microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma.Mol Syst Biol. 2010;6:402.
5. Geuze HJ,Slot JW,Strous GJ,Lodish HF,Schwartz AL.Intracellular site of asialoglycoprotein receptor-ligand uncoupling: double-label immunoelectron microscopy during receptor-mediated endocytosis.Cell. 1983;32:277-287.
6. Geuze HJ,Slot JW,Strous GJ,Lodish HF,Schwartz AL.Immunocytochemical localization of the receptor for asialoglycoprotein in rat liver cells.J Cell Biol. 1982;92:865-870.
7. Huang XB,Li J,Zheng L,Zuo GH,Han KQ,Li HY,Liang P.Bioinformatics Analysis Reveals Potential Candidate Drugs for HCC.Pathol Oncol Res. 2013;19:251-258.
8. Hwang LH.Gene therapy strategies for hepatocellular carcinoma.J Biomed Sci. 2006;13:453-468.
9. Hyodo I,Mizuno M,Yamada G,Tsuji T.Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma.Liver. 1993;13:80-85.
10. Ise H,Nikaido T,Negishi N,Sugihara N,Suzuki F,Akaike T,Ikeda U.Effective hepatocyte transplantation using rat hepatocytes with low asialoglycoprotein receptor expression.Am J Pathol. 2004;165:501-510.
11. Ishibashi S,Hammer RE,Herz J.Asialoglycoprotein receptor deficiency in mice lacking the minor receptor subunit.J Biol Chem. 1994;269:27803-27806.
12. Ivanovska I,Zhang C,Liu AM,Wong KF,Lee NP,Lewis P,Philippar U,Bansal D,Buser C,Scott M,Mao M,Poon RT,Fan ST,Cleary MA,Luk JM,Dai H.Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma.PLoS One. 2011;6:e24582.
13. Jain RK.Transport of molecules in the tumor interstitium: a review.Cancer Res. 1987;47:3039-3051.
14. Julyan PJ,Seymour LW,Ferry DR,Daryani S,Boivin CM,Doran J,David M,Anderson D,Christodoulou C,Young AM,Hesslewood S,Kerr DJ.Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.J Control Release. 1999;57:281-290.
15. Keating GM,Santoro A.Sorafenib: a review of its use in advanced hepatocellular carcinoma.Drugs. 2009;69:223-240.
16. Laurent-Puig P,Zucman-Rossi J.Genetics of hepatocellular tumors.Oncogene. 2006;25:3778-3786.
17. Lee JS,Chu IS,Mikaelyan A,Calvisi DF,Heo J,Reddy JK,Thorgeirsson SS.Application of comparative functional genomics to identify best-fit mouse models to study human cancer.Nat Genet. 2004;36:1306-1311.
18. Matsuura S,Nakada H,Sawamura T,Tashiro Y.Distribution of an asialoglycoprotein receptor on rat hepatocyte cell surface.J Cell Biol. 1982;95:864-875.
19. Mok TS,Leung TW,Brown G,Moyses C,Chan AT,Yeo W,Wong H,Chak K,Johnson P.A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer.Acta Oncol. 2004;43:245-251.
20. Mok WC,Wasser S,Tan T,Lim SG.Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.World J Gastroenterol. 2012;18:3527-3536.
21. Packer A.Second-generation models.Nat Rev Genet. 2004;5:888.
22. Piddock LJ.Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria.Clin Microbiol Rev. 2006;19:382-402.
23. Rozema DB,Lewis DL,Wakefield DH,Wong SC,Klein JJ,Roesch PL,Bertin SL,Reppen TW,Chu Q,Blokhin AV,Hagstrom JE,Wolff JA.Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes.Proc Natl Acad Sci U S A. 2007;104:12982-12987.
24. Seymour LW,Ferry DR,Anderson D,Hesslewood S,Julyan PJ,Poyner R,Doran J,Young AM,Burtles S,Kerr DJ.Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.J Clin Oncol. 2002;20:1668-1676.
25. Siegel R,Naishadham D,Jemal A.Cancer statistics, 2013.CA Cancer J Clin. 2013;63:11-30.
26. Skelton MR,O'Neil B.Targeted therapies for hepatocellular carcinoma.Clin Adv Hematol Oncol. 2008;6:209-218.
27. Spiess M.The asialoglycoprotein receptor: a model for endocytic transport receptors.Biochemistry. 1990;29:10009-10018.
28. Sun H,Teng M,Liu J,Jin D,Wu J,Yan D,Fan J,Qin X,Tang H,Peng Z.FOXM1 expression predicts the prognosis in hepatocellular carcinoma patients after orthotopic liver transplantation combined with the Milan criteria.Cancer Lett. 2011;306:214-222.
29. Terada T,Iwai M,Kawakami S,Yamashita F,Hashida M.Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting.J Control Release. 2006;111:333-342.
30. Tozawa R,Ishibashi S,Osuga J,Yamamoto K,Yagyu H,Ohashi K,Tamura Y,Yahagi N,Iizuka Y,Okazaki H,Harada K,Gotoda T,Shimano H,Kimura S,Nagai R,Yamada N.Asialoglycoprotein receptor deficiency in mice lacking the major receptor subunit. Its obligate requirement for the stable expression of oligomeric receptor.J Biol Chem. 2001;276:12624-12628.
31. Trere D,Fiume L,De Giorgi LB,Di Stefano G,Migaldi M,Derenzini M.The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells.Br J Cancer. 1999;81:404-408.
32. Varshosaz J,Hassanzadeh F,Sadeghi H,Khadem M.Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma.J Liposome Res. 2012;22:224-236.
33. Vogel CL,Cobleigh MA,Tripathy D,Gutheil JC,Harris LN,Fehrenbacher L,Slamon DJ,Murphy M,Novotny WF,Burchmore M,Shak S,Stewart SJ.First-line Herceptin monotherapy in metastatic breast cancer. Oncology.61 Suppl. 2001;2:37-42.
34. Wall DA,Hubbard AL.Galactose-specific recognition system of mammalian liver: receptor distribution on the hepatocyte cell surface.J Cell Biol. 1981;90:687-696.
35. Wang R,Ferrell LD,Faouzi S,Maher JJ,Bishop JM.Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.J Cell Biol. 2001;153:1023-34.
36. Xu C,Lee SA,Chen X.RNA interference as therapeutics for hepatocellular carcinoma.Recent Pat Anticancer Drug Discov. 2011;6:106-115.